

CONTENTS

- 1. Company Overview**
- 2. Business Overview**
 - 1) Glucose Monitoring Business**
 - 2) POCT Business**
- Appendix**

DISCLAIMER

This presentation contains certain forward-looking statements that are derived from the company's forecasts, business plans and strategy. While these statements represent our current judgment on future prospects, actual results may differ materially due to various factors such as modification of business plans and strategies, delays in bringing products to market, changes in regulations and so forth.

Although i-SENS, Inc. has taken great care in preparing the material, the company does not guarantee the accuracy or completeness of the material in this presentation.

THIS MATERIAL IS NEITHER AN OFFER NOR INTENDED AS INVESTMENT, FINANCIAL, LEGAL, ACCOUNTING, TAX OR ANY OTHER ADVICE.

All materials have been prepared in accordance with K-IFRS. All figures in USD are converted using the exchange rate of 1 USD = 1,100 KRW.

Sensing Ahead, Caring More



1. Company Overview

2. Business Overview

- 1) Glucose Monitoring Business
- 2) POCT Business

Appendix


1. Market Overview: In Vitro Diagnostics

In Vitro Diagnostics (IVD)



The Largest Market in Medical Devices

IVD by Segment



i-SENS Business Segments

Glucose Monitoring

• Blood Glucose Monitoring (BGM)

• Continuous Glucose Monitoring (CGM)

POCT (Point-of-Care Testing)

i-SENS Sales Ratio

87%

Launch in 2023

13%

Source: Biotech Policy Research Center (2021)

* Based on 2021 revenue

2. i-SENS Product Portfolio

Glucose Monitoring

BGM (Blood Glucose Monitoring)



Test Strip



Meter

CGM (Continuous Glucose Monitoring)



In Development

POCT (Point-of-Care Testing)

POCT Devices



BGM for Hospital Use



HbA1c Analyzer



Blood Electrolyte Analyzer



Blood Gas Analyzer



PT/INR * Analyzer


Immunoassay Analyzer




In Development

* PT/INR(Prothrombin Time and International Normalized Ratio)

3. History: Steady and Stable Growth



4. Business Structure and Global Partners



5. Key Strengths of i-SENS

1 Core Business

- BGM

2 Growth Engine

- CGM
- POCT

3 Production

- High-capacity manufacturing
- International standard quality

4 Technology

- Outstanding biosensor technology
- Latest IT connectivity

Sensing Ahead, Caring More



- ## 1. Company Overview


2. Business Overview

1) Glucose Monitoring Business

2) POCT Business

Appendix

1. Diabetes Population Continues to Increase



Source: IDF (International Diabetes Federation)



Patients

Type 1

Type 2



Devices

CGM



BGM

2. China BGM Market

i-SENS Chinese Factory :
Expected to achieve cost competitiveness

→ Domestic
→ Export

Number of Diabetes Patients
(Unit: million)




Source: IDF (International Diabetes Federation), Glucose Monitoring Global Market, IQ41 Research & Consultancy

3. Growth of i-SENS BGM Market Share

i-SENS BGM sales

(Unit: \$ million)




4. i-SENS BGM Accuracy Meets High Standards




: Stricter Regulatory Standards Make it Favorable for i-SENS

Method Comparison(System Accuracy)





CareSens "S Fit" U.S. Clinical Results Satisfy 2016 OTC FDA Standard



2016 OTC FDA Guidance: Criteria A: 95% of all measured values should be within $\pm 15\%$ of the reference results & Criteria B: 99% of all measured values should be within $\pm 20\%$ of the reference results

5. Continuous Glucose Monitoring : New Opportunities

Glucose Level Continuously Measured on a Real-time Basis

Type	 CGM	 BGM
Where to use	Abdomen, upper arm	Fingertip
Measurement sample	Interstitial fluid (No blood drawn)	Capillary blood
Strengths	Diabetes management easier, less pain than BGM	High accuracy and reasonable price
Challenges	High price	Frequent measurements, penetration pain

Where We Are




6. Strip Capacity & Production

Highly Efficient Manufacturing Facilities with Annual Capacity of **2.1 billion Strips**

(Single-shift basis)

Strip Capacity and Production



※ Gross Production Capacity : Average daily production times No. of working days times No. of operating months ※ Based on one shift (8 working hours/day)



1. Company Overview

2. Business Overview

1) Glucose Monitoring Business

2) POCT Business

Appendix

1. i-SENS POCT

POCT (Point-of-Care Testing)

- POCT means tests performed at the time and place of patient care




POCT



Central Laboratory


i-SENS POCT Strategy

- Enhance brand value through offering our reliable products to professionals



i-SENS POCT Highlights

- Our devices utilize consumables (such as sensor, cartridge, reagents, etc)



2. POCT: Blood Electrolyte / Gas Analyzer (1)

Blood Electrolytes, Gas **i-Smart** series



- Since February 2009
- #1 in Korea (Installed base)

Blood Gas & Metabolites **i-SmartCare** series



- Focus on decentralization of Blood Gas Testing

- Tests for imbalances in pH, blood minerals, oxygen, carbon dioxide and metabolites as those can indicate or monitor certain serious medical conditions on critically ill patients
- Global market size for Blood Gas and Electrolyte estimated at US\$1.4 billion*

* Connectivity & Quality Management solutions in Development

** Source: Zion Market Research Analysis 2018

2. POCT: Blood Electrolyte / Gas Analyzer (2)

Micro-sensor Technology

Small size with High reliability and accurate results

One Touch Care


Intuitive touch-screen SW, Audio & light guidance

All-in-1 Cartridge Technology

Closed system, Captive recurring revenues
No on-site maintenance. No refrigerated storage

Connectivity & Quality Management

Automatic, continuous, on board



Micro-sensor



All-in-one Cartridge



One Touch Care

Care **CONNECT**

Care **QM**

Connectivity & Quality Management

Optimized for testing decentralization & POCT deployment

3. POCT: High-value Diagnostic Devices for Professionals

Diabetes Care for Hospital Use

HbA1c Analyzer



ACR Cartridge

BGM For Hospital Use



- Detect the average blood glucose level during the past three months with a single test

- Easy hospital data management

Coagulation Analyzer

PT/INR Analyzer



- Monitor the therapeutic range of a long-term anti-coagulant such as warfarin

* ACR (Albumin/Creatinine Ratio)

*PT/INR (Prothrombin Time and International Normalized Ratio)

4. POCT: Immunoassay Analyzer

Background

- A platform which measures the important cardiac markers in emergency care
- Based on i-SENS proprietary cartridge system

Features

- Smart Integration: Internal centrifuge process eliminates hematocrit bias
 - Does not require any pretreatment of the whole blood
- Up to 4 samples can be tested with random access
 - Suitable for emergency care



Appendix 1. Company Profile



Appendix 2. Manufacturing supported by strong R&D

Investing in Biosensor R&D

Co-founders Profile



Geun Sig Cha (Chairman, CEO)

- BS, MS Korea University, Dept. of Chemistry
- PhD, University of Michigan
- '91~'15 Professor at Kwangwoon University, Dept. of Chemistry
- Present: Emeritus Professor at Kwangwoon Univ.
- '00~Present: i-SENS, Inc., CEO, Chairman
- '11 Ministerial Citation Award for Korea's Startup Exhibition (Ministry of Knowledge Economy)
- '14 Ministerial Citation of Merit Award for Medical Device Industry (Ministry of Health and Welfare)
- '16 Presidential Citation of Merit for Electronics& IT Day (Ministry of Trade, Industry and Energy)




Hakhyun Nam (President, CEO)


- BS, Seoul National University, Dept. of Chemistry
- PhD Michigan State University
- '92 ~ '15 Professor at Kwangwoon University, Dept. of Chemistry
- Present: Emeritus Professor at Kwangwoon University.
- '00 ~ Present : i-SENS, Inc., CEO, President
- '08 Citation of the excellent researcher for R&D in health and medical science technology (Minister of Health and Welfare)
- '11 Citation of Merit Award for Industrial-education Cooperation
- '11 Citation of Merit Award for Industrial Technology
- '19 KITA's top export award (Ministry of Trade, Industry and Energy)
- '19 Citation of Science, Information and Communication Day (Prime Minister)

R&D Expenses

- Ratio of R&D expenses to revenue
- R&D investments (\$ million) (Parent company basis)



Number of Employees



(As of December 31st, 2021)